Key scientific papers
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
Commentary by Tatjana Stankovic and Marwan Kwok
Institute of Cancer and Genomic Sciences, University of Birmingham, UK
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome
Commentary by Tatjana Stankovic
Institute of Cancer and Genomic Sciences, University of Birmingham, UK
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features
Summary by Pauline Robbe
Department of Oncology, University of Oxford, Oxford, UK
Functional mapping of PHF6 complexes in chromatin remodeling, replication dynamics and DNA repair
Commentary by Tatjana Stankovic
Institute of Cancer and Genomic Sciences, University of Birmingham, UK
Extrinsic Interactions in the Microenvironment In Vivo Activate an Antiapoptotic Multidrug-Resistant Phenotype in CLL
(published in Blood Advances on the 25th of August 2021)
Commentary by Tatjana Stankovic
Institute of Cancer and Genomic Sciences, University of Birmingham, UK
Commentary by Tatjana Stankovic and Marwan Kwok
Institute of Cancer and Genomic Sciences, University of Birmingham, UK
Enhanced IL-9 secretion by p66Shc-deficient CLL cells modulates the chemokine landscape of the stromal microenvironment
Tatjana Stankovic
Institute of Cancer and Genomic Sciences, University of Birmingham, UK
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
By Anthony Mato, Lindsey Roeker, Nicole Lamanna, John Allan, Lori Leslie, John Pagel , Krish Patel, Anders Osterborg, Daniel Wojenski, Manali Kamdar, Scott F Huntington, Matthew S Davids, Jennifer R Brown, Darko Antic, Ryan Jacobs, Inhye Ahn, Jeffrey Pu, Krista Isaac, Paul Barr, Chaitra Ujjani, Mark Geyer, Ellin Berman, Andrew Zelenetz, Nikita Malakhov, Richard Furman, Michael Koropsak, Neil Bailey, Lotta Hanson, Guilherme Perini, Shuo Ma, Christine Ryan, Adrian Wiestner, Craig Portell, Mazyar Shadman, Elise Chong, Danielle Brander, Suchitra Sundaram, Amanda Seddon, Erlene Seymour, Meera Patel, Nicolas Martinez-Calle, Talha Munir, Renata Walewska, Angus Broom, Harriet Walter, Dima El-Sharkawi, Helen Parry, Matthew Wilson, Piers Patten, José-Ángel Hernández-Rivas, Fatima Miras, Noemi Fernández Escalada, Paola Ghione, Chadi Nabhan, Sonia Lebowitz, Erica Bhavsar, Javier López-Jiménez, Daniel Naya, Jose Antonio Garcia-Marco, Sigrid S Skånland, Raul Cordoba, Toby Eyre
Fine tuning of p53 functions between normal and leukemic cells: a new strategy
for the treatment of chronic lymphocytic leukemia
Tatjana Stankovic
Institute of Cancer and Genomic Sciences, University of Birmingham, UK
Non-genotoxic MDM2 inhibition selectively induces
pro-apoptotic p53 gene signature in chronic lymphocytic
leukemia cells
by Carmela Ciardullo, Erhan Aptullahoglu, Laura Woodhouse, Wei-Yu Lin, Jonathan P. Wallis,
Helen Marr, Scott Marshall, Nick Bown, Elaine Willmore, and John Lunec